

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 4 OCTOBER 2001


Jeff Lloyd, Patent Attorney



Patent Application
Docket No. UGR-100X
Serial No. 09/629,596

RECEIVED
OCT 12 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : P. Ponnaluri
Art Unit : 1627
Applicants : Michael J. Adang, Laura M. Kasman
Serial No. : 09/629,596
Filed : July 31, 2000
For : Phage Display of a Biologically Active *Bacillus thuringiensis* Toxin

Assistant Commissioner for Patents
Washington, D.C. 20231

PR 7/00
10-17-01


SUBMISSION OF SEQUENCE LISTING UNDER 1.821

Sir:

Transmitted herewith is a sequence listing under 37 CFR 1.821 through 1.825 for the above-identified patent application. A Communication from the Examiner and a Notice to Comply with Sequence Rules 37 CFR 1.821-1.825 were received from the Patent and Trademark Office, and copies of the Notices are enclosed herewith.

The sequence is submitted in computer readable format and on paper. I hereby certify that the paper and computer readable copies are the same and that no new material is added by this submission.

Respectfully submitted,


Jeff Lloyd
Patent Attorney

Registration No. 35,589

Phone No.: 407-426-7500

Address: 1000 Legion Place, Suite 1750
Orlando, FL 32801

JL/gm

Attachments: Sequence listing on paper; computer readable format containing the same information; copies of Notices from PTO

COPY




UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/529,596	07/31/00	ADAMS	M UGR-100X

HM12/0924

JEFF LLOYD
2421 NW 41ST STREET
SUITE A1
GAINESVILLE FL 32606-6669



PONNALURI, P

ART UNIT

PAPER NUMBER

1627

DATE MAILED:

09/24/01

TECH CENTER 1600/2300

OCT 12 2001


RECEIVED

Please find below and/or attached an Office communication concerning this application proceeding.

Commissioner of Patents and Trademarks

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/629,596	7/31/00		



EXAMINER	
P. Ponnaluri	
ART UNIT	PAPER NUMBER
1627	6

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.


APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to P. Ponnaluri whose telephone number is (703) 305-3884. The examiner can normally be reached on Monday through Friday from 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat, can be reached at (703)308-2439. The fax number for this group is (703)305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-0196.


P. Ponnaluri
Patent Examiner
Technology center 1600
Art Unit 1627
21 September 2001


PADMASHRI PONNALURI
PRIMARY EXAMINER

Application No.: 09/629,596

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: All the sequences in the file do not comply with the sequence rules

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE